Ryvu Therapeutics (RVU.WA) Stock Price

Ryvu Therapeutics Price

GPW·CLOSED
14.88PLN+0.14 (+0.95 %)
Market closed

Revenue has compounded at 19.2% per year over the past 12 years to 77.97 M PLN. Earnings per share have grown at 100.0% per year over the last 5 years. Ryvu Therapeutics's net margin stands at -142.9%, up from -202.5% several years earlier. Analysts set a median price target of 32.64 PLN, implying 119.4% above the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 8% above its 52-week low.

Ryvu Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Ryvu Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Ryvu Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Ryvu Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Ryvu Therapeutics Stock Price History
DateRyvu Therapeutics Price
8/4/202614.88 PLN
7/31/202614.74 PLN
7/30/202615.06 PLN
7/29/202615.00 PLN
7/28/202615.00 PLN
7/27/202615.02 PLN
7/24/202615.00 PLN
7/23/202614.92 PLN
7/22/202614.36 PLN
7/21/202614.90 PLN
7/20/202614.58 PLN
7/17/202614.90 PLN
7/16/202614.98 PLN
7/15/202615.30 PLN
7/14/202615.58 PLN
7/13/202616.00 PLN
7/10/202615.32 PLN
7/9/202614.84 PLN
7/8/202615.04 PLN
7/7/202614.84 PLN
7/6/202614.62 PLN
7/3/202615.46 PLN
7/2/202615.30 PLN
7/1/202613.96 PLN
6/30/202613.76 PLN
6/29/202613.90 PLN
6/26/202613.84 PLN
6/25/202614.00 PLN
6/24/202614.00 PLN
6/23/202614.26 PLN
6/22/202614.28 PLN
6/19/202614.30 PLN
6/18/202614.18 PLN
6/17/202614.70 PLN
6/16/202614.36 PLN
6/15/202615.04 PLN
6/12/202615.38 PLN
6/11/202615.40 PLN
6/10/202615.38 PLN
6/9/202615.62 PLN
6/8/202615.84 PLN
6/5/202614.20 PLN
6/3/202614.28 PLN
6/2/202614.76 PLN
6/1/202615.88 PLN
5/29/202616.50 PLN
5/28/202616.48 PLN
5/27/202616.96 PLN
5/26/202617.36 PLN
5/25/202617.70 PLN
5/22/202618.00 PLN
5/21/202618.96 PLN
5/20/202622.65 PLN
5/19/202622.80 PLN
5/18/202622.50 PLN
5/15/202622.95 PLN
5/14/202622.85 PLN
5/13/202623.35 PLN
5/12/202624.00 PLN
5/11/202623.50 PLN
5/8/202623.20 PLN
5/7/202623.40 PLN
5/6/202624.00 PLN
5/5/202624.20 PLN
5/4/202624.30 PLN
4/30/202624.00 PLN
4/29/202623.40 PLN
4/28/202623.90 PLN
4/27/202623.55 PLN
4/24/202623.95 PLN
4/23/202623.50 PLN
4/22/202624.45 PLN
4/21/202625.30 PLN
4/20/202625.05 PLN
4/17/202625.55 PLN
4/16/202625.00 PLN
4/15/202625.45 PLN
4/14/202625.00 PLN
4/13/202624.50 PLN
4/10/202624.00 PLN
4/9/202623.05 PLN
4/8/202623.55 PLN
4/7/202623.40 PLN
4/2/202622.90 PLN
4/1/202623.00 PLN
3/31/202622.60 PLN
3/30/202620.70 PLN
3/27/202620.90 PLN
3/26/202621.90 PLN
3/25/202621.40 PLN
3/24/202621.80 PLN
3/23/202621.60 PLN
3/20/202622.00 PLN
3/19/202621.70 PLN
3/18/202623.35 PLN
3/17/202623.30 PLN
3/16/202623.90 PLN
3/13/202624.50 PLN
3/12/202624.60 PLN
3/11/202625.30 PLN
3/10/202625.30 PLN
3/9/202625.50 PLN
3/6/202625.55 PLN
3/5/202626.00 PLN
3/4/202625.60 PLN
3/3/202625.00 PLN
3/2/202625.95 PLN
2/27/202626.35 PLN
2/26/202625.55 PLN
2/25/202625.35 PLN
2/24/202625.60 PLN
2/23/202626.60 PLN
2/20/202625.60 PLN
2/19/202625.50 PLN
2/18/202625.90 PLN
2/17/202625.60 PLN
2/16/202625.30 PLN
2/13/202625.15 PLN
2/12/202625.55 PLN
2/11/202625.70 PLN
2/10/202625.65 PLN
2/9/202625.00 PLN
2/6/202624.75 PLN
2/5/202624.15 PLN
2/4/202625.35 PLN
2/3/202625.10 PLN
2/2/202625.70 PLN
1/30/202625.85 PLN
1/29/202626.20 PLN
1/28/202626.90 PLN
1/27/202626.50 PLN
1/26/202626.45 PLN
1/23/202626.90 PLN
1/22/202627.25 PLN
1/21/202626.30 PLN
1/20/202626.00 PLN
1/19/202626.80 PLN
1/16/202627.00 PLN
1/15/202627.20 PLN
1/14/202627.50 PLN
1/13/202627.50 PLN
1/12/202627.80 PLN
1/9/202627.65 PLN
1/8/202627.65 PLN
1/7/202627.80 PLN
1/5/202627.50 PLN
1/2/202627.15 PLN
12/30/202527.10 PLN
12/29/202526.75 PLN
12/23/202525.35 PLN
12/22/202525.80 PLN
12/19/202525.60 PLN
12/18/202525.30 PLN
12/17/202525.50 PLN
12/16/202525.20 PLN
12/15/202526.35 PLN
12/12/202526.30 PLN
12/11/202526.00 PLN
12/10/202527.00 PLN
12/9/202529.05 PLN
12/8/202529.50 PLN
12/5/202529.90 PLN
12/4/202528.75 PLN
12/3/202529.00 PLN
12/2/202528.70 PLN
12/1/202528.10 PLN
11/28/202528.10 PLN
11/27/202528.50 PLN
11/26/202528.15 PLN
11/25/202525.55 PLN
11/24/202524.50 PLN
11/21/202523.40 PLN
11/20/202524.10 PLN
11/19/202524.70 PLN
11/18/202523.60 PLN
11/17/202524.15 PLN
11/14/202524.70 PLN
11/13/202524.95 PLN
11/12/202524.15 PLN
11/10/202523.10 PLN
11/7/202522.95 PLN
11/6/202524.00 PLN
11/5/202524.30 PLN
11/4/202524.80 PLN
11/3/202524.90 PLN
10/31/202523.80 PLN
10/30/202524.30 PLN
10/29/202525.00 PLN
10/28/202524.65 PLN
10/27/202525.00 PLN
10/24/202524.65 PLN
10/23/202524.85 PLN
10/22/202525.50 PLN
10/21/202525.60 PLN
10/20/202525.80 PLN
10/17/202526.00 PLN
10/16/202527.00 PLN
10/15/202526.80 PLN
10/14/202525.75 PLN
10/13/202526.20 PLN
10/10/202526.80 PLN
10/9/202527.60 PLN
10/8/202528.15 PLN
10/7/202528.15 PLN
10/6/202528.40 PLN
10/3/202528.35 PLN
10/2/202528.10 PLN
10/1/202528.00 PLN
9/30/202527.80 PLN
9/29/202527.95 PLN
9/26/202526.90 PLN
9/25/202527.35 PLN
9/24/202527.30 PLN
9/23/202527.40 PLN
9/22/202527.90 PLN
9/19/202527.60 PLN
9/18/202527.80 PLN
9/17/202527.40 PLN
9/16/202527.40 PLN
9/15/202528.40 PLN
9/12/202528.65 PLN
9/11/202528.50 PLN
9/10/202528.30 PLN
9/9/202528.40 PLN
9/8/202528.30 PLN
9/5/202527.30 PLN
9/4/202527.80 PLN
9/3/202527.80 PLN
9/2/202527.30 PLN
9/1/202527.90 PLN
8/29/202528.90 PLN
8/28/202529.20 PLN
8/27/202528.80 PLN
8/26/202529.60 PLN
8/25/202529.40 PLN
8/22/202529.25 PLN
8/21/202529.95 PLN
8/20/202530.00 PLN
8/19/202530.00 PLN
8/18/202530.05 PLN
8/14/202530.30 PLN
8/13/202530.30 PLN
8/12/202530.70 PLN
8/11/202530.15 PLN
8/8/202530.45 PLN
8/7/202530.95 PLN
8/6/202530.40 PLN
Access this data via the Eulerpool API
Get Free API Key

Ryvu Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
38.95 M PLN
-70.69 M PLN
-83.78 M PLN
Jan 1, 2023
46.86 M PLN
-97.38 M PLN
-92.11 M PLN
Jan 1, 2024
77.97 M PLN
-121.97 M PLN
-111.44 M PLN
Jan 1, 2025 (e)
84.18 M PLN
-84.18 M PLN
-107.62 M PLN
Jan 1, 2026 (e)
110.40 M PLN
-110.40 M PLN
-50.40 M PLN
Jan 1, 2027 (e)
106.88 M PLN
-106.88 M PLN
-2.54 M PLN
Jan 1, 2028 (e)
141.00 M PLN
-141.00 M PLN
8.55 M PLN
Jan 1, 2029 (e)
27.00 M PLN
-27.00 M PLN
0.00 PLN

Ryvu Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 1:23 AM
 
REVENUEM PLN
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM PLN
EBITM PLN
EBIT MARGIN%
NET INCOMEM PLN
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
41.0048.0067.0077.003.0015.0011.0038.0046.0077.0084.00110.00106.00141.0027.00107.00
46.4317.0739.5814.93-96.10400.00-26.67245.4521.0567.399.0930.95-3.6433.02-80.85296.30
70.7370.8361.1966.23-300.0040.00-227.27142.1143.4870.1370.1370.1370.1370.1370.1370.13
29.0034.0041.0051.00-9.006.00-25.0054.0020.0054.0058.9177.1474.3498.8818.9475.04
2.00-1.0012.00-13.00-45.00-35.00-78.00-70.00-97.00-121.00-84.00-110.00-106.00-141.00-27.00-107.00
4.88-2.0817.91-16.88-1,500.00-233.33-709.09-184.21-210.87-157.14-100.00-100.00-100.00-100.00-100.00-100.00
6.002.006.00–285.00-31.00-79.00-83.00-92.00-111.00-107.00-50.00-2.008.00––
20.00-66.67200.00––-110.88154.845.0610.8420.65-3.60-53.27-96.00-500.00––
13.0513.7413.7715.5215.9716.7718.3618.3622.9023.1223.1223.1223.1223.1223.1223.12
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Ryvu Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Ryvu Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Ryvu Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Ryvu Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Ryvu Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Ryvu Therapeutics stock margins

The Ryvu Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ryvu Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ryvu Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
44.00 %
-227.92 %
-202.47 %
Jan 1, 2021
-228.30 %
-705.21 %
-706.94 %
Jan 1, 2022
-1.65 %
-181.50 %
-215.12 %
Jan 1, 2023
44.80 %
-207.80 %
-196.57 %
Jan 1, 2024
69.58 %
-156.43 %
-142.92 %
Jan 1, 2025 (e)
69.58 %
-100.00 %
-127.86 %
Jan 1, 2026 (e)
69.58 %
-100.00 %
-45.65 %
Jan 1, 2027 (e)
69.58 %
-100.00 %
-2.38 %

Ryvu Therapeutics Stock Revenue, EBIT, Earnings per Share

The Ryvu Therapeutics earnings per share therefore indicates how much revenue Ryvu Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.93 PLN
-2.13 PLN
-1.89 PLN
Jan 1, 2021
0.61 PLN
-4.30 PLN
-4.31 PLN
Jan 1, 2022
2.12 PLN
-3.85 PLN
-4.56 PLN
Jan 1, 2023
2.05 PLN
-4.25 PLN
-4.02 PLN
Jan 1, 2024
3.37 PLN
-5.28 PLN
-4.82 PLN
Jan 1, 2025 (e)
3.64 PLN
-3.64 PLN
-4.66 PLN
Jan 1, 2026 (e)
4.78 PLN
-4.78 PLN
-2.18 PLN
Jan 1, 2027 (e)
4.62 PLN
-4.62 PLN
-0.11 PLN

Ryvu Therapeutics business model & stock analysis

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer.

Ryvu Therapeutics SWOT Analysis

Strengths

Ryvu Therapeutics SA has a strong portfolio of innovative therapies and drugs.

The company has a highly skilled and experienced management team.

Ryvu Therapeutics SA has established partnerships with renowned research institutions.

Weaknesses

The company is dependent on the success of its drug development pipeline.

Ryvu Therapeutics SA is a relatively small player in the pharmaceutical industry.

The company may face challenges in securing sufficient funding for its research and development activities.

Opportunities

There is a growing demand for effective and personalized treatments in the healthcare market.

Ryvu Therapeutics SA can leverage advancements in technology to enhance its drug discovery process.

The company can explore expansion into new geographical markets.

Threats

The pharmaceutical industry is highly competitive and subject to stringent regulatory requirements.

Ryvu Therapeutics SA may face challenges in obtaining intellectual property protection for its innovations.

Unexpected clinical trial outcomes or failures could negatively impact the company's reputation and financial stability.

Ryvu Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Ryvu Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Ryvu Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Ryvu Therapeutics shares outstanding

The number of shares of Ryvu Therapeutics was 23.12 M in 2025. This indicates how many shares Ryvu Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
16.77 M Stocks
Jan 1, 2021
18.36 M Stocks
Jan 1, 2022
18.36 M Stocks
Jan 1, 2023
22.90 M Stocks
Jan 1, 2024
23.12 M Stocks
Jan 1, 2025 (e)
23.12 M Stocks
Jan 1, 2026 (e)
23.12 M Stocks
Jan 1, 2027 (e)
23.12 M Stocks

Current Ryvu Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
75.00 % (6)
Hold
25.00 % (2)
Sell
0.00 % (0)
12M Price Target
32.64
Last Price
16.02
Currency
PLN
12M Return Potential
103.75 %
LTM Return
0 %

Ryvu Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
9/8/2021-PLN-6.39 MPLN-2021 Q2
3/16/2021-PLN-6.09 MPLN-2020 Q4

Ryvu Therapeutics shareholder structure

% Name
17.22373%
Przewiezlikowski (Pawel)
Przewiezlikowski (Pawel)
9.22371%
Towarzystwo Funduszy Inwestycyjnych Allianz Polska SA
Towarzystwo Funduszy Inwestycyjnych Allianz Polska SA
8.29334%
BioNTech SE
BioNTech SE
6.00789%
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA
5.93729%
Wesolowski (Tadeusz)
Wesolowski (Tadeusz)
3.56981%
Sieczkowski (Boguslaw Stanislaw)
Sieczkowski (Boguslaw Stanislaw)

Ryvu Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
68.2%
Float Shares
-
Shares Outstanding
-

Ryvu Therapeutics Executives and Management Board

10 members · 0 % women

VV

Mr. Vatnak Vat-ho

Chief Business Officer, Member of the Management Board

937,984.00 PLN

Management

KB

Dr. Krzysztof Brzozka

Vice President of the Management Board, Chief Scientific Officer

595,507.00 PLN
KS

Dr. Kamil Sitarz

Chief Operating Officer, Member of the Management Board

485,541.00 PLN

Board of Directors

PR

Dr. Piotr Romanowski

Independent Chairman of the Supervisory Board · since 2010

150,477.00 PLN
RC

Mr. Rafal Chwast

Independent Member of the Supervisory Board

150,477.00 PLN
TW

Dr. Tadeusz Wesolowski

Vice Chairman of the Supervisory Board · since 2011

148,255.00 PLN
AG

Mr. Axel Glasmacher

Member of the Supervisory Board

148,255.00 PLN
TT

Mr. Thomas Turalski

Member of the Supervisory Board

148,255.00 PLN
SF

Dr. Scott Fields

Member of the Supervisory Board

–

Frequently asked questions about Ryvu Therapeutics

Ryvu Therapeutics SA operates under a business model focused on developing innovative therapies to address unmet medical needs. They specialize in research and development of novel small molecule drugs targeting cancer and inflammatory diseases. As a biopharmaceutical company, Ryvu Therapeutics is dedicated to discovering and advancing potential treatments through rigorous scientific methods. By leveraging their expertise in drug discovery and understanding of disease biology, they strive to deliver breakthrough medicines that can improve patient outcomes. Ryvu Therapeutics aims to bring innovative therapies to market that have the potential to transform patient care in areas where medical needs are not yet met.

Ryvu Therapeutics SA is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Ryvu Therapeutics SA in the market include Genmab A/S, Incyte Corporation, and Gilead Sciences, Inc. These companies are also active in the biopharmaceutical industry, focusing on developing and commercializing innovative therapies. However, Ryvu Therapeutics SA brings unique offerings to the market with its portfolio of proprietary drug candidates and therapeutic platforms. With its commitment to advancing precision oncology and targeted therapies, Ryvu Therapeutics SA distinguishes itself from its competitors and aims to make a significant impact in the field of biopharmaceuticals.

Ryvu Therapeutics SA is a biopharmaceutical company founded in 2007 in Poland. It focuses on discovering and developing innovative small molecule therapies for the treatment of various cancers. Ryvu Therapeutics SA has a strong research and development pipeline, with a particular emphasis on targeted therapies that can potentially address the underlying mechanisms driving cancer growth. The company has made significant progress in preclinical and early clinical stages, with several promising drug candidates. Ryvu Therapeutics SA aims to improve patient outcomes and contribute to the advancement of cancer treatment through its dedication to scientific excellence and innovative drug development approaches.

Ryvu Therapeutics SA has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in February 2019, raising funds to support its research and development efforts. In October 2019, Ryvu Therapeutics SA entered into a collaboration agreement with an international pharmaceutical company for the development of innovative cancer therapies. Another noteworthy achievement is the advancement of its internal pipeline, particularly the progress made in the clinical development of its investigational drug candidates. These achievements demonstrate Ryvu Therapeutics SA's commitment to advancing novel therapies and establishing strategic partnerships in the field of oncology.

Ryvu Therapeutics SA is primarily present in Poland, where it is headquartered.

Ryvu Therapeutics SA is a biotechnology company that is committed to transforming patient care and addressing unmet medical needs. The company's corporate philosophy revolves around innovation, scientific excellence, and a patient-centric approach. Ryvu Therapeutics SA values the power of collaboration and partnerships, aiming to drive advancements in the field of oncology and rare diseases. With a focus on research and development, Ryvu Therapeutics SA strives to bring novel therapies to the market that have the potential to significantly improve and extend the lives of patients. This dedication to scientific discovery and a result-driven mindset defines the core values of Ryvu Therapeutics SA.

Analysts currently set an average price target of 54.50 PLN for the Ryvu Therapeutics stock (median: 32.64 PLN), implying +240.2 % versus the latest price. The consensus is based on 8 analyst ratings.

Ryvu Therapeutics Analyst Price Targets 2026

8 analysts currently rate the Ryvu Therapeutics stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Ryvu Therapeutics to generate revenue of 110.40 M PLN and earnings per share of -2.18 PLN.

Ryvu Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Ryvu Therapeutics share trades at 3.46 EUR (14.88 PLN).

The Ryvu Therapeutics share (RVU.WA) is listed on 4 stock exchanges, including: Frankfurt (9Y4.F), London (0RKT.L).

Ryvu Therapeutics SA is a research-driven biotechnology company focused on developing novel therapies for cancer and inflammatory diseases. The company collaborates closely with researchers and academics to make breakthrough discoveries in oncology research and translate them into clinical applications. The business model of Ryvu Therapeutics SA is based on combining innovative research with numerous partnerships with academic institutions to develop novel drugs that can be used against cancer and inflammatory diseases. The company's goal is to improve the lives of cancer patients and expand the boundaries of medicine through the development of innovative technologies and new treatment options. To achieve this, the company has a wide range of products in the pipeline, including small molecule inhibitors, biologics, and immunotherapies. In addition to developing new treatment options, Ryvu Therapeutics SA also works closely with academic institutions to make new discoveries in oncology research and translate them into clinical applications. The company aims to attract new partners and investors to expand its business model and venture into new therapy areas. Overall, Ryvu Therapeutics SA's business model offers a wide range of products and services tailored to the needs of cancer patients. The company combines innovative research with numerous partnerships with academic institutions to make groundbreaking discoveries in oncology research and translate them into clinical applications. With a wide range of products in the pipeline and a dedicated leadership team, Ryvu Therapeutics SA is well positioned to improve the lives of cancer patients and promote the growth of the company.

The expected revenue of Ryvu Therapeutics is 110.40 M PLN. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Ryvu Therapeutics is -50.40 M PLN. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Ryvu Therapeutics is currently -6.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ryvu Therapeutics stock.

The price-to-sales ratio (P/S) of Ryvu Therapeutics is currently 3.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ryvu Therapeutics stock.

The Eulerpool Quality Score for Ryvu Therapeutics is 3/10.

The ISIN of Ryvu Therapeutics is PLSELVT00013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Ryvu Therapeutics is A1JUH2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Ryvu Therapeutics is RVU.WA. The ticker symbol is used to trade Ryvu Therapeutics shares on the stock exchange.

Ryvu Therapeutics paid dividends every year for the past 0 years.

Ryvu Therapeutics is assigned to the 'Health' sector.

The dividends of Ryvu Therapeutics are distributed in PLN.

All fundamentals and in-depth analysis of Ryvu Therapeutics

Our stock analysis for Ryvu Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ryvu Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Ryvu Therapeutics Stock
Ryvu Therapeutics Revenue→
Ryvu Therapeutics Stock
Ryvu Therapeutics Net Income→
Ryvu Therapeutics Stock
Ryvu Therapeutics P/E→
Ryvu Therapeutics Stock
Ryvu Therapeutics P/S→
Ryvu Therapeutics Stock
Ryvu Therapeutics EBIT→
Ryvu Therapeutics Stock
Ryvu Therapeutics Dividend→
Ryvu Therapeutics Stock
Ryvu Therapeutics Directors Dealings→
Ryvu Therapeutics Stock
Ryvu Therapeutics Stocks→
Ryvu Therapeutics Stock
Ryvu Therapeutics Market capitalization→
Ryvu Therapeutics Stock
Ryvu Therapeutics Debt→
Ryvu Therapeutics Stock
Ryvu Therapeutics Liabilities→
Ryvu Therapeutics Stock
Ryvu Therapeutics Equity→
Ryvu Therapeutics Stock
Ryvu Therapeutics AAQS→
Ryvu Therapeutics Stock
Ryvu Therapeutics Employees→
Ryvu Therapeutics Stock
Ryvu Therapeutics ROE→
Ryvu Therapeutics Stock
Ryvu Therapeutics ROA→
Ryvu Therapeutics Stock
Ryvu Therapeutics ROCE→
Ryvu Therapeutics Stock
Ryvu Therapeutics News→
Ryvu Therapeutics Stock
Ryvu Therapeutics Analyst Price Targets→

Health Stocks

S Biomedics CorYojbaba CoS.A.M Trade (Asia) PteRyman HealthcareS&S Healthcare HoldingRxsightS2Medical AB (publ)RVL PharmaceuticalsSAB BiotherapeuticsRubicon OrganicsSabaa International Company for Pharmaceutical & Chemical IndustriesRua Life SciencesAll Stocks A–Z →